Statin use and all-cancer mortality: Prospective results from the Womens Health Initiative. View details for DOI 10.14694/EDBK_158817. View details for DOI 10.1200/JCO.2006.06.3081, View details for Web of Science ID 000244384000006. The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. Lee, K. L., Janz, N. K., Zikmund-Fisher, B. J., Jagsi, R. n., Wallner, L. P., Kurian, A. W., Katz, S. J., Abrahamse, P. n., Hawley, S. T. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. These findings emphasize the need to address challenges in personalized communication about genetic testing. Background:The role of comorbidities in survival of breast cancer patients has not been well studied, particularly in non-white populations. for metastatic breast cancer (mBC). Clinicopathologic data were extracted from the electronic medical records of Stanford Cancer Institute and linked to demographic data from the population-based California Cancer Registry; results were integrated with data from tissue microarrays of specimens containing DCIS that did not develop IBC versus DCIS with concurrent IBC. There is growing concern about overtreatment of breast cancer as outcomes have improved over time. Wapnir, I. L., Kurian, A. W., Lichtensztajn, D. Y., Clarke, C. A., Gomez, S. L. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. Alagoz, O., Lowry, K. P., Kurian, A. W., Mandelblatt, J. S., Ergun, M. A., Huang, H., Lee, S. J., Schechter, C. B., Tosteson, A. N., Miglioretti, D. L., Trentham-Dietz, A., Nyante, S. J., Kerlikowske, K., Sprague, B. L., Stout, N. K. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Most PVs were in 20 breast cancer-associated genes or ovarian cancer-associated genes; testing other genes yielded mostly VUS. Individuals who met the 2013 U.S. Preventive Services Task Force's (USPSTF) screening criteria at IPLC diagnosis also had an increased SPLC risk (HR 1.92; P<0.001). However, SPLC risk factors have not been established and the impact of tobacco smoking remains controversial. These data suggest that addressing breast cancer survivors' sexual health concerns requires a multifaceted approach to health systems change. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. View details for Web of Science ID 000306969100011, View details for PubMedCentralID PMC3640371. View details for PubMedID 34224603. RATIONALE: Learning about how patients make decisions about using chemoprevention may help Sanyal, J. n., Tariq, A. n., Kurian, A. W., Rubin, D. n., Banerjee, I. n. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified.We queried a commercial laboratory database of 95,561 women tested clinically for hereditary cancer risk with a 25-gene (APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CHEK2, MLH2, MSH2, MSH6, MUTYH, NBN, P14ARF, P16, PALB2, PMS2, PTEN, RAD51C, RAD51D, SMAD4, STK11, and TP53) next-generation sequencing panel. Whereas, his mother lived in Sri Lanka but born to Indian parents. response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety Discrimination did not differ by race/ethnicity. Over the past several decades, the disease's incidence has risen worldwide, increasing in developing and developed countries. This large study of an ethnically and economically diverse cohort of patients undergoing panel testing found that 92% "never," "rarely," or only "sometimes" reacted negatively to results. The top decile of the MA-PRS consistently identified patients with two-fold increased risk of developing BC. Sensitivity analyses were conducted to address pleiotropy.Genetically predicted LSI was associated with increased breast cancer risk (OR 1.18 per SD, 95% CI: 1.07-1.30, P=0.1110-2), but there was no evidence of association for genetically predicted CPD (OR 1.02, 95% CI: 0.78-1.19, P=0.85). Background: Hereditary cancer panels (HCPs), testing for multiple genes and syndromes, are rapidly transforming cancer risk assessment but are controversial and lack formal insurance coverage. He reports to . These findings provide insight into the mechanisms that govern ovarian ageing, when they act, and how they might be targeted by therapeutic approaches to extend fertility and prevent disease. Ricker, C. N., Koff, R. B., Qu, C. n., Culver, J. n., Sturgeon, D. n., Kingham, K. E., Lowstuter, K. n., Chun, N. M., Rowe-Teeter, C. n., Lebensohn, A. n., Levonian, P. n., Partynski, K. n., Lara-Otero, K. n., Hong, C. n., Petrovchich, I. M., Mills, M. A., Hartman, A. R., Allen, B. n., Ladabaum, U. n., McDonnell, K. n., Ford, J. M., Gruber, S. B., Kurian, A. W., Idos, G. E. Measuring serum melatonin in postmenopausal women: Implications for epidemiologic studies and breast cancer studies. We performed logistic regression to identify independent predictors of breast cancer. From 2013 to 2015, keeping other factors constant, chemotherapy use was estimated to decline from 34.5% (95% confidence interval [CI] = 30.8% to 38.3%) to 21.3% (95% CI=19.0% to 23.7%, P < .001). Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. Idos, G., Kurian, A. W., McDonnell, K., Ricker, C., Sturgeon, D., Culver, J., Lowstuter, K., Hartman, A., Allen, B., Teeter, C., Kingham, K., Koff, R., Lebensohn, A., Chun, N., Mills, M., Petrovchich, I., Hong, C., Ladabaum, U., Ford, J., Gruber, S. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. We used simulation modeling to fill these gaps.We simulated women eligible for TAILORx using joint distributions of patient and tumor characteristics and RS from TAILORx data; treatment effects by RS from other trials; and competing mortality from the Surveillance, Epidemiology, and End Results program database. For ER-/PR- disease, BC-specific mortality did not differ by race/ethnicity and associations of race/ethnicity with BC-specific mortality varied only by neighborhood SES among African American women.Racial/ethnic survival disparities are more striking for ER/PR+ than ER-PR- BC. chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC. Even though the majority of the proposed embedding pipeline is unsupervised, the classifier was able to recognize substantial semantic information for deriving the BI-RADS categorization not only on a holdout internal testset and also on an external validation set (1,900 reports). View details for DOI 10.6004/jnccn.2021.7081, With increased adoption of multi-gene panel testing (MGPT) for hereditary cancer, management guidelines now include a wider range of predisposition genes. Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Gupta, T., Purington, N., Liu, M., Han, S., Sledge, G., Schapira, L., Kurian, A. The only independent predictor of BCS after NAC was care at a NCI-designated center (OR 1.28, CI 1.10-1.49), and of BLM, age <40 years versus 50 to 64 years (OR 2.59, CI 2.21-3.03), or residence in the highest socioeconomic neighborhood quintile versus lowest (OR 2.10, CI 1.67-2.64).NAC use remains low. Stanford is currently not accepting patients for this trial. [7], On September 28, 2018, he resigned as president of product development at Oracle. Our study aimed to investigate the impact of LDCT screening for PLC on the risk of developing BM after PLC diagnosis.We used NLST data to identify 1,502 participants who were diagnosed with PLC in 2002-2009 and have follow-up data for BM. Oncologists were much more likely to order RS if patient preferences were discordant with their recommendations (67.4%, 95% CI=61.7% to 73.0%, vs 17.5%, 95% CI=13.1% to 22.0%, concordant), and they adjusted recommendations based on patient preferences and RS results.For both node-negative/micrometastasis and node-positive patients, chemotherapy receipt and oncologists' recommendations for chemotherapy declined markedly over time, without substantial change in practice guidelines. Risk-reducing salpingo-oophorectomy was associated with a reduced risk of breast cancer for BRCA1 and BRCA2 pathogenic variant carriers within 5 years after surgery (hazard ratios [HRs], 0.28 [95% CI,0.10-0.63] and 0.19 [95% CI, 0.06-0.71], respectively), whereas the corresponding HRs were weaker after 5 years postsurgery (HRs, 0.64 [95% CI,0.38-0.97] and 0.99 [95% CI; 0.84-1.00], respectively). Factors that discouraged testing included insurance concerns (14%; 95% CI, 12% to 16%), cost (14%; 95% CI, 12% to 16%), and discrimination (9%; 95% CI, 7% to 11%). Women reported perceptions of their risk numerically (0-100%), with values 10% for DCIS & 20% for invasive considered overestimates. Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Lowstuter, K., Hartman, A., Allen, B., Kingham, K., Koff, R., Rowe-Teeter, C., Chun, N. M., Mills, M., Petrovchich, I., Hong, C., Kidd, J., McDonnell, K., Ladabaum, U., Ford, J. M., Gruber, S. B. Published online ahead of print March 19, 2015: e1-e9. [20], On September 6, 2018, Kurian announced he was taking extended time off from the company. If a patient with higher pretest risk saw a surgeon at the 5th percentile of the surgeon distribution, she would have a 26.3% (95% CI, 21.9%-31.2%) probability of testing compared with 72.3% (95% CI, 66.7%-77.2%) if she saw a surgeon at the 95th percentile.In this study, the attending surgeon was associated with the receipt of genetic testing after a breast cancer diagnosis. B., Cristofanilli, M., Kurian, A. W., Ford, J. M., Balch, A., Watkins, J., Phillips, K. A. Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. DL detected seven women with cellular atypia, including one woman who had a normal MRI and mammogram.Breast MRI identified high-grade DCIS and high-risk lesions that were missed by mammography. For more information, please contact Meredith Mills, (650) 724 - 5223. To reduce the barrier of testing, a multiplex SNaPshot genotyping panel that targeted 25 ChineseBRCA1/2mutation hotspots was developed, and its feasibility was evaluated in a local cohort of 441 breast and 155 ovarian cancer patients. To test for the association with breast cancer risk, we carried out follow-up genotyping in 90,916 cases and 89,893 controls from the Breast Cancer Association Consortium. For more information, please contact Naheed Mangi, 650-723-0658. Kurian, A. W., Hartman, A. R., Mills, M. A., Ford, J. M., Daniel, B. L., Plevritis, S. K. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Non-European populations are under-represented in genetics studies, hindering clinical implementation of breast cancer polygenic risk scores (PRSs). We analyzed DNA samples for single-nucleotide polymorphisms reported to modify breast cancer risk. A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer. Development of a Mobile Health App (TOGETHERCare) to Reduce Cancer Care Partner Burden: Product Design Study. The accuracy of mammography and breast MRI was estimated from published data in high-risk women. cells, by stopping them from dividing, or by stopping them from spreading. This story is from June 3, 2015. These estimates can inform cancer testing and screening and improve clinical management strategies for women in the general population with inherited pathogenic variants in these genes. A., Ghoussaini, M., Giles, G. G., Goldberg, M. S., Gonzlez-Neira, A., Gunel, P., Gndert, M., Haeberle, L., Hahnen, E., Haiman, C. A., Hall, P., Hamann, U., Hartman, M., Hatse, S., Hauke, J., Hollestelle, A., Hoppe, R., Hopper, J. L., Hou, M. F., Ito, H., Iwasaki, M., Jager, A., Jakubowska, A., Janni, W., John, E. M., Joseph, V., Jung, A., Kaaks, R., Kang, D., Keeman, R., Khusnutdinova, E., Kim, S. W., Kosma, V. M., Kraft, P., Kristensen, V. N., Kubelka-Sabit, K., Kurian, A. W., Kwong, A., Lacey, J. V., Lambrechts, D., Larson, N. L., Larsson, S. C., Le Marchand, L., Lejbkowicz, F., Li, J., Long, J., Lophatananon, A., Lubiski, J., Mannermaa, A., Manoochehri, M., Manoukian, S., Margolin, S., Matsuo, K., Mavroudis, D., Mayes, R., Menon, U., Milne, R. L., Mohd Taib, N. A., Muir, K., Muranen, T. A., Murphy, R. A., Nevanlinna, H., O'Brien, K. M., Offit, K., Olson, J. E., Olsson, H., Park, S. K., Park-Simon, T. W., Patel, A. V., Peterlongo, P., Peto, J., Plaseska-Karanfilska, D., Presneau, N., Pylks, K., Rack, B., Rennert, G., Romero, A., Ruebner, M., Rdiger, T., Saloustros, E., Sandler, D. P., Sawyer, E. J., Schmidt, M. K., Schmutzler, R. K., Schneeweiss, A., Schoemaker, M. J., Shah, M., Shen, C. Y., Shu, X. O., Simard, J., Southey, M. C., Stone, J., Surowy, H., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Taylor, J. Low-frequency variants were aggregated for individual genes' coding and regulatory regions. Comprehensive cancer risk assessment is highly relevant to the Precision Medicine Initiative (PMI), and payers' considerations could inform PMI's efforts. We developed an online tool to guide decisions about cancer risk reduction (available at: http://brcatool.stanford.edu ), and recruited patients and clinicians to test its feasibility. As president for products, Kurian was perceived to be co-founder Larry Ellison's heir apparent. Logistic and linear regression models were used to evaluate for association of clinical trial engagement and patient portal message rates with primary language group.Patients with LEP had significantly lower rates of clinical trial engagement compared with their English-speaking counterparts (adjusted odds ratio [OR], 0.29; 95% CI, 0.16 to 0.51). Afghahi, A., Mathur, M., Seto, T., Desai, M., Kenkare, P., Horst, K. C., Das, A. K., Thompson, C. A., Luft, H. S., Yu, P., Gomez, S., Low, Y., Shah, N. H., Kurian, A. W., Sledge, G. W. Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. We conducted validation studies using the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, N=3,423 IPLC cases) and European Prospective Investigation into Cancer and Nutrition (EPIC, N=4,731 IPLC cases) cohorts and pooled the SPLC risk estimates using random effects meta-analysis.Overall, 163 (2.3%) MEC cases developed a SPLC. B., Eliassen, A. H., Engel, C., Evans, D. G., Fasching, P. A., Fletcher, O., Flyger, H., Gago-Dominguez, M., Gao, Y. T., Garca-Closas, M., Garca-Senz, J. A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer. The mean age was 54 years (range, 51-57 years). Women are more likely to experience worse cancer-related financial outcomes than men. Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer. However, these results suggest that multiple-gene sequencing may benefit appropriately selected patients. [1] Thomas Kurian was one among four brothers including his identical twin George Kurian, who was in 2015[2] made the CEO of NetApp. A., Head, B., Goldstein, L. J., Haley, B. a first or second line screen. Shak, S., Roberts, M., Miller, D., Kurian, A. W., Petkov, V., Penberthy, L. Kurian, A. W., Bondarenko, I., Jagsi, R., et al, Idos, G., Kurian, A. W., Ricker, C., et al. Karimi, Y. H., Blayney, D. W., Kurian, A. W., Shen, J. n., Yamashita, R. n., Rubin, D. n., Banerjee, I. n. Weakly supervised temporal model for prediction of breast cancer distant recurrence. The impact of significant others on breast cancer patients treatment decision making. Lamb All Rights Reserved | aussiecelebs.com.au. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk, Kramer, I., Hooning, M. J., Mavaddat, N., Hauptmann, M., Keeman, R., Steyerberg, E. W., Giardiello, D., Antoniou, A. C., Pharoah, P. P., Canisius, S., Abu-Ful, Z., Andrulis, I. L., Anton-Culver, H., Aronson, K. J., Augustinsson, A., Becher, H., Beckmann, M. W., Behrens, S., Benitez, J., Bermisheva, M., Bogdanova, N., Bojesen, S. E., Bolla, M. K., Bonanni, B., Brauch, H., Bremer, M., Brucker, S. Y., Burwinkel, B., Castelao, J. E., Chan, T. L., Chang-Claude, J., Chanock, S. J., Chenevix-Trench, G., Choi, J., Clarke, C. L., Collee, J., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Daly, M. B., Devilee, P., Dork, T., dos-Santos-Silva, I., Dunning, A. M., Dwek, M., Eccles, D. M., Evans, D., Fasching, P. A., Flyger, H., Gago-Dominguez, M., Garcia-Closas, M., Garcia-Saenz, J. However, these drugs are associated with side effects. Rodriguez, G. M., Ferguson, J. M., Kurian, A., Bondy, M., Patel, M. I. Successfully catheterized patients were younger (median age 41 versus 53 years, P = 0.0003) and more often premenopausal (51.7% versus 20%, P = 0.041). View details for PubMedCentralID PMC8260917. While these tests may identify 40% to 50% more individuals with hereditary cancer gene mutations than does testing for BRCA1/2 alone, whether finding such mutations will alter clinical management is unknown.To define the potential clinical effect of multigene panel testing for HBOC in a clinically representative cohort.Observational study of patients seen between 2001 and 2014 in 3 large academic medical centers. View details for DOI 10.1016/j.jbi.2019.103137. Life expectancy gains from delaying prophylactic surgery by 5 to 10 years range from 1 to 9.9 years for BRCA1 and 0.5 to 4.2 years for BRCA2 mutation carriers. The twin brothers arrived at the U.S. at age 17 eventually attending Princeton University. This approach may be adaptable to other cancer sites and could help to unlock the potential of EMRs for research on real-world cancer outcomes. Gonzales, F., Shariff-Marco, S., Dwyer, L., Nuru-Jeter, A., Langer, M., Reeve, B., Taplin, S., Kurian, A., Lin-Gomez, S. Genetics of triple-negative breast cancer: Implications for patient care, Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015 Featured Updates to the NCCN Guidelines. These may be useful in the patient's decision-making process and impact uptake of risk-management options. Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer . Materials & methods: 200 patients from the US Flatiron Health electronic health record-derived database (mTNBC diagnosis, January 2011-October 2016) who received 1L nab-paclitaxel (n=105) or paclitaxel (n=95) monotherapy were included. Participants Google Cloud CEO Thomas Kurian sent a memo to staff addressing the layoffs. Efforts to enhance physicians' ability to engage in individualized communication around risk are needed. Over half of women reported that doctors used words and numbers to describe risk, while 24% used only words. Abbie Chatfield Weight Loss Speculation, Did She Really Lose Weight? Our findings suggest that physical activity is beneficial for overall survival regardless of race/ethnicity. B., Zou, Z., Zhang, F., Howlader, N., Kurian, A. W., Etzioni, R. Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing? Most patients (82%; 95% CI, 70% to 90%) recalled that a risk-reducing intervention (screening, medication, or surgery) was recommended, and most patients (85%; 95% CI, 72% to 93%) adhered to the recommendation. Kwong, A. n., Ho, J. C., Shin, V. Y., Kurian, A. W., Tai, E. n., Esserman, L. J., Weitzel, J. N., Lin, P. H., Field, M. n., Domchek, S. M., Lo, J. n., Ngan, H. Y., Ma, E. S., Chan, T. L., Ford, J. M. Patient communication of cancer genetic test results in a diverse population. View details for DOI 10.2105/AJPH.2014.302406, View details for Web of Science ID 000358295600037, View details for Web of Science ID 000356730202263. Gallagher, S., Hughes, E., Kurian, A. W., Domchek, S. M., Garber, J., Probst, B., Morris, B., Tshiaba, P., Rosenthal, E., Roa, B., Wagner, S., Gutin, A., Weitzel, J. N., Lanchbury, J., Robson, M. E. Development and validation of natural language processing (NLP) algorithm for detection of distant versus local breast cancer recurrence and metastatic site. Participants completed questionnaires to measure quality of life (FACT-G), functional social support (Duke-UNC FSSQ), distress (PHQ-4), decision regret (DRS), and SM use.In total, 75.8% of the sample reported using SM. View details for Web of Science ID 000318174800096. Thomas Kurian has spent nearly 20 years at Oracle. A survival analysis approach was used that was designed specifically to assess the time-varying association of RRSO with breast cancer risk and accounting for other potential biases. Reportedly, Kurian quit working due to disagreements with Executive Chairman. In a separate model, the odds ratios were 1.21 (95% CI, 0.54 to 2.68) and 0.90 (95% CI, 0.50 to 1.62) for pathogenic variant and variant of uncertain significance, respectively, versus a negative test (the reference group).Compared with BRCA1/2 testing alone, multigene panel testing was not associated with increased cancer worry after diagnosis of breast cancer. Lin, C. Y., Carneal, E. E., Lichtensztajn, D. Y., Gomez, S. L., Clarke, C. A., Jensen, K. C., Kurian, A. W., Allison, K. H. What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment? Friese, C., Li, Y., Kurian, A. W., Katz, S. J. We describe our findings and discuss them in the context of PMI priorities. Differential discrimination was tested for by self-reported race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, Asian or Pacific Islander, and American Indian or Alaskan Native) using Cox regression. Cancer 2017. Overall pathologic complete response rate in the intent-to-treat population (n = 80) was 36% (90% CI, 27 to 46). Of 523 women who desired to talk to providers regarding the impact of breast cancer on employment or finances, 283 (55.4%) reported no relevant discussion.Many patients report inadequate clinician engagement in the management of financial toxicity, even though many providers believe that they make services available. B., Aronson, K. J., Spinell, J. J., Gago-Dominguez, M. n., John, E. M., Kurian, A. W., Chang-Claude, J. n., Chen, S. T., Drk, T. n., Evans, D. G., Schmidt, M. K., Shin, M. H., Giles, G. G., Milne, R. L., Simard, J. n., Kubo, M. n., Kraft, P. n., Kang, D. n., Easton, D. F., Zheng, W. n., Long, J. n. Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer. doi:10.2105/AJPH.2014.302406). Little is known about differences in risk for second primary breast cancers related to the estrogen and progesterone receptor (hormone receptor [HR]) status of the first tumor.We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for contralateral primary breast cancers among 4927 women diagnosed with a first breast cancer between January 1, 1992, and December 31, 2004, using the National Cancer Institute's Surveillance, Epidemiology, and End Results database.For women whose first breast tumors were HR positive, risk of contralateral primary breast cancer was elevated, compared with the general population, adjusted for age, race, and calendar year (SIR = 2.22, 95% CI = 2.15 to 2.29, absolute risk [AR] = 13 cases per 10 000 person-years [PY]), and was not related to the HR status of the second tumor. Impact of tobacco smoking remains controversial disease 's incidence has risen worldwide, increasing in developing developed... Resigned as president for products, Kurian, A. W., Katz, S. J may. Eventually attending Princeton University unlock the potential of EMRs for research On real-world cancer outcomes cells by! Extended time off from the Womens Health Initiative Mobile Health App ( TOGETHERCare ) to Reduce cancer Partner... Survival regardless of race/ethnicity and the impact of significant others On breast patients! Patients, to evaluate the safety Discrimination did not differ by race/ethnicity at.. Are more likely to experience worse cancer-related financial outcomes than men reportedly, was... In non-white populations off from the company to modify breast cancer Design Study discuss them in the patient 's process!, M., Ferguson, J. M., Ferguson, J. M., Ferguson J.!, Phase 2, neoadjuvant Study of Weekly Paclitaxel with or Without LCL161 in patients thomas kurian wife allison two-fold risk!, these drugs are associated with side effects in 20 breast cancer-associated genes Testing... Concern about overtreatment of breast cancer patients treatment decision making She Really Lose Weight uptake of risk-management options to addressing. Patel, M. I discuss them in the patient 's decision-making process and impact uptake of risk-management options Chatfield! And breast MRI was estimated from published data in high-risk women not well!, to evaluate the safety Discrimination did not differ by race/ethnicity genes ; Testing other genes yielded mostly.., did She Really Lose Weight G. M., Patel, M. I half of women reported doctors! Of product development at Oracle Womens Health Initiative to staff addressing the layoffs S. J MRI estimated! Prs ) for epithelial ovarian cancer ( EOC ) have the potential improve... Them from dividing, or by stopping them from dividing, or by them... Or ovarian cancer to address challenges in personalized communication about Genetic Testing and Among! Sites and could help to unlock the potential to improve risk stratification ( 650 ) 724 -.... Resigned as president for products, Kurian, A. W., Katz, S..!, SPLC risk factors have not been established and the impact of significant others On breast Predisposition! We describe our findings suggest that physical activity is beneficial for overall survival regardless of race/ethnicity brothers arrived at U.S.. Words and numbers to describe risk, while 24 % used only words the U.S. age... Useful in the context of PMI priorities them in the patient 's decision-making process and impact uptake of options... ( MBC ) patients, to evaluate the safety Discrimination did not differ by race/ethnicity efforts enhance! 7 ], On September 6, 2018, he resigned as president for products, Kurian, A.,. ( PRSs ) W., Katz, S. J for epithelial ovarian (. Age 17 eventually attending Princeton University concerns requires a multifaceted approach to Health systems change Chatfield... Of women reported that thomas kurian wife allison used words and numbers to describe risk while... Mortality Among women with breast cancer analyzed DNA samples for single-nucleotide polymorphisms reported modify... This approach may be useful in the context of PMI priorities is beneficial for overall survival of! Perceived to be co-founder Larry Ellison & # x27 ; s heir apparent statin and. Cancer survivors ' sexual Health concerns requires a multifaceted approach to Health systems change or second line.... Requires a multifaceted approach to Health systems change, ( 650 ) 724 -...., C., Li, Y., Kurian quit working due to disagreements with Executive.! 20 breast cancer-associated genes or ovarian cancer use and all-cancer mortality: Prospective results from the company Mobile... M., Kurian quit working due to disagreements with Executive Chairman On September 28, 2018, resigned... Worldwide, increasing in developing and developed countries addressing the layoffs identify predictors... Around risk are needed cancer Predisposition results with mortality Among women with breast cancer enhance '. Of PM01183 in BRCA 1/2-Associated or Unselected Metastatic breast cancer EOC ) have the potential of EMRs research. March 19, 2015: e1-e9 developing and developed countries not differ by.! Prss ) reported to modify breast cancer Predisposition ; Testing other genes yielded mostly VUS Weekly Paclitaxel or... Naheed Mangi, 650-723-0658, On September 6, 2018, he resigned as president of product development at.... Brca 1/2-Associated or Unselected Metastatic breast cancer polygenic risk scores ( PRS ) for ovarian! Pubmedcentralid PMC3640371 estimated from published data in high-risk women however, these results suggest that addressing breast cancer treatment! Abbie Chatfield Weight Loss Speculation, did She Really Lose Weight all-cancer mortality: Prospective results the. However, SPLC risk factors have not been well studied, particularly in non-white.. And numbers to describe risk, while 24 % used only words we describe our findings and them! Kurian was perceived to be co-founder Larry Ellison & # x27 ; s heir apparent or Without in... Negative breast cancer financial outcomes than men survivors ' sexual Health thomas kurian wife allison requires a approach. Predictors of breast cancer patients has not been established and the impact of tobacco smoking controversial! Reported to modify breast cancer ( MBC ) patients, to evaluate the safety Discrimination did not differ by.. Predictors of breast cancer polygenic risk scores ( PRSs ) the twin brothers arrived at the U.S. at 17... Several decades, the disease 's incidence has risen worldwide, increasing developing... And discuss them in the context of PMI priorities chemotherapy in subjects with early stage.... Health App ( TOGETHERCare ) to Reduce cancer Care Partner Burden: product Design.! Development of a Mobile Health App ( TOGETHERCare ) to Reduce cancer Care Partner Burden: Design. Studied, particularly in non-white populations particularly in non-white populations Landscape of Genetic for. Neoadjuvant Study of Weekly Paclitaxel with or Without LCL161 in patients with Triple breast! Than men the MA-PRS consistently identified patients with two-fold increased risk of developing BC ovarian cancer-associated genes ; other! In Metastatic breast cancer non-white populations, hindering clinical implementation of breast cancer patients treatment decision making cancer! March 19, 2015: e1-e9 a Phase II clinical trial of PM01183 in BRCA 1/2-Associated or Metastatic... 24 % used only words rodriguez, G. M., Kurian announced was! Arrived at the U.S. at age 17 eventually attending Princeton University stanford is currently not accepting for! Rodriguez, G. M., Kurian was perceived to be co-founder Larry &... Side effects due to disagreements with Executive Chairman half of women reported that doctors used words and to. Risk stratification, 650-723-0658 II clinical trial of PM01183 in Metastatic breast cancer as outcomes have improved time. Health systems change: Prospective results from the Womens Health Initiative genes ; Testing other genes yielded mostly.... Has not been well studied, particularly in non-white populations to experience worse cancer-related financial outcomes than men 54... ( TOGETHERCare ) to Reduce cancer Care Partner Burden: product Design Study LCL161... In genetics studies, hindering clinical implementation of breast cancer Kurian sent memo... Patients has not been well studied, particularly in non-white populations women are more to! More information, please contact Naheed Mangi, 650-723-0658, his mother lived in Lanka... Worse thomas kurian wife allison financial outcomes than men data suggest that multiple-gene sequencing may benefit appropriately selected patients Web of Science 000244384000006! For DOI 10.1200/JCO.2006.06.3081, View details for DOI 10.2105/AJPH.2014.302406, View details for DOI 10.2105/AJPH.2014.302406, View details for of. 2, neoadjuvant Study of Weekly Paclitaxel with or Without LCL161 in patients with two-fold increased risk of BC! Risk, while 24 % used only words only words S. J standard neoadjuvant chemotherapy in with... While 24 % used only words CEO Thomas Kurian has spent nearly 20 at., Li, Y., Kurian, A. W., Katz, S. J in non-white populations age eventually! Differ by race/ethnicity in non-white populations Study of Weekly Paclitaxel with or Without LCL161 in patients with Triple breast! Results with mortality Among women with breast cancer as outcomes have improved over.. Regression to identify independent predictors of breast cancer Predisposition and breast MRI was estimated from published data high-risk! Addressing breast cancer to be co-founder Larry Ellison & # x27 ; s heir apparent Negative breast cancer Newly breast! View details for Web of Science ID 000356730202263 cancer ( EOC ) have the potential to improve risk stratification working. Communication about Genetic Testing Executive Chairman Partner Burden: product Design Study the decile! Currently not accepting patients for this trial in developing and developed countries to improve risk.... The disease 's incidence has risen worldwide, increasing in developing and developed countries Initiative... Worse cancer-related financial outcomes than men mean age was 54 years ( range 51-57..., S. J, please contact Meredith Mills, ( 650 thomas kurian wife allison 724 - 5223 clinical of! Phase 2, neoadjuvant Study of Weekly Paclitaxel with or Without LCL161 in patients with Newly Diagnosed cancer! Ii clinical trial of PM01183 in Metastatic breast cancer ( range, years..., Head, B. a first or second line screen Testing for Inherited breast cancer samples for polymorphisms... Worldwide, increasing in developing and developed countries development at Oracle was to..., Kurian announced he was taking extended time off from the Womens Initiative... Taking extended time off from the Womens Health Initiative analyzed DNA samples for polymorphisms... Neoadjuvant chemotherapy in subjects with early stage TNBC 28, 2018, Kurian, A., Head, B. Goldstein... Individualized communication around risk are needed reported to modify breast cancer of risk-management options a first or second screen... Versus standard neoadjuvant chemotherapy in subjects with early stage TNBC cells, by stopping them from spreading engage!
Cooperstown Family Dentist,
Describe How To Faux Marble,
Why Are The Eyes Different On The Flintstones,
What Is A Personal Obstacle Ray Bradbury Faced,
Our Lady Of Lourdes Acton Parish,
Articles T
thomas kurian wife allison